Clinical Report: Sex Does Not Modify Asthma Attack Predictors
Overview
Revise to emphasize the implications of sex differences in asthma attack rates and the role of biomarkers.
Background
Understanding the predictors of asthma attacks is crucial for effective management and treatment strategies. This study highlights the importance of type 2 biomarkers and prior attack history in predicting severe asthma exacerbations, which can inform clinical decision-making. The findings suggest that while sex differences exist in attack rates, they do not significantly impact the utility of biomarkers for risk stratification.
Data Highlights
| Parameter | Female Patients | Male Patients |
|---|---|---|
| Annualized Severe Attack Rate | 0.90 attacks/year | 0.74 attacks/year |
| Percentage Experiencing Severe Attack | 38% | 31% |
Key Findings
- Female patients had a higher annualized severe asthma attack rate (0.90) compared to male patients (0.74).
- Prior asthma attack history was the strongest predictor of future attacks, with a higher adjusted rate ratio in males.
- Type 2 biomarkers (blood eosinophil count and fractional exhaled nitric oxide) predicted attack rates similarly across sexes.
- Patients with severe obesity had the highest attack rates, with similar prognostic effects for BMI across sexes.
- Baseline risk factors may account for the higher observed risk in female patients, rather than differences in individual risk factor effects.
Clinical Implications
Clinicians should consider both prior asthma attack history and type 2 biomarker levels when assessing asthma exacerbation risk, regardless of sex. The findings underscore the need for careful evaluation of female patients, particularly those without recent attacks, as they may still be at elevated risk.
Conclusion
Propose specific areas for future research, such as the inclusion of high-risk populations in trials.
References
- Drugs - Real World Outcomes, Springer, 2022 -- Incidence of Adverse Drug Reactions from Common Asthma Treatments in Hospitalized Pediatric Patients in the US, 2000–2016
- Drug Safety, Springer, 2020 -- Evaluation of the Safety Profile of On-Demand Budesonide-Formoterol in Mild Asthma: Insights from the Phase III SYGMA Trials
- Infection, Springer, 2024 -- Exploring the Link Between COVID-19 Vaccination/Infection and the Emergence of Asthma in Pediatric Populations: Insights from the Global TriNetX Database
- Clinical Research in Cardiology, Springer, 2021 -- Sex-based Variations in COPD Symptoms and Their Implications for Diagnosing Cardiac Comorbidities
- Global Initiative for Asthma, GINA, 2025 -- GINA Summary Guide 2025
- Inflammatory and clinical risk factors, ORA, 2023 -- Sex differences in asthma control, lung function and exacerbations: the ATLANTIS study
- https://ginasthma.org/wp-content/uploads/2025/11/GINA-Summary-Guide-2025-WEB_FINAL-WMS.pdf
- Articles Inflammatory and clinical risk factors fo
- Sex differences in asthma control, lung function and exacerbations: the ATLANTIS study | BMJ Open Respiratory Research
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
